Hemab Therapeutics raises $157 million in Series C financing, led by Sofinnova Partners, to advance treatments for bleeding disorders.
Amount Raised
$157 Million
Round Type
Series C
CopenhagenBiotechnologyHealth CareTherapeuticsInvestors
Description
Hemab Therapeutics has completed a $157 million Series C financing round to advance next-generation treatments for bleeding disorders. The funding will support registration studies for their therapeutic candidates following successful Phase 2 trials. The round saw participation from prominent investors, including Sofinnova Partners and a large global sovereign wealth fund. This financing positions Hemab to expand its clinical pipeline significantly.
Quick answer
Hemab Therapeutics raised $157 Million in a Series C round, dated October 27, 2025. Investors: RA Capital Management, Large Long Only Global Asset Management Company, Healthcap, Maj Invest Equity, Avoro Ventures, Avoro Capital Advisors, Large Global Sovereign Wealth Fund and Novo Holdings. Hemab Therapeutics is based in Copenhagen, Capital Region Of Denmark, Denmark.
- How much did Hemab Therapeutics raise?
- Hemab Therapeutics raised $157 Million in a Series C round on October 27, 2025.
- Who invested in Hemab Therapeutics?
- RA Capital Management, Large Long Only Global Asset Management Company, Healthcap, Maj Invest Equity, Avoro Ventures, Avoro Capital Advisors, Large Global Sovereign Wealth Fund and Novo Holdings are named as investors in this round.
- What does Hemab Therapeutics do?
- Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders.
- Where is Hemab Therapeutics based and how big is it?
- Hemab Therapeutics is based in Copenhagen, Capital Region Of Denmark, Denmark. Fundz records about 90 employees.
- Who are the decision-makers at Hemab Therapeutics?
- Fundz holds 2 contacts at Hemab Therapeutics, including the Senior Vice President, Development Operations. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Hemab Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Cayuga Biotech raised $8M (Seed) on December 11, 2025.
- Denali Therapeutics raised $200M (Post-IPO Equity) on December 10, 2025.
- EpilepsyGTx raised $33M (Series A) on December 10, 2025.
- Dyne Therapeutics raised $350M (Post-IPO Equity) on December 10, 2025.
- D3 Bio raised $108M (Series B) on December 10, 2025.
- Aprea Therapeutics raised $3.1M on December 10, 2025.
Who to call at Hemab Therapeutics, and when
A new round usually means Hemab Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Hemab Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Hemab Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Hemab Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Hemab Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Hemab Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.